Nature’s Sunshine Products, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 12, 2024. This is an annual report, not a standalone fourth-quarter report, and the provided filing does not give a clear standalone Q4 financial result.
Business context
Nature’s Sunshine manufactures and sells nutritional and personal-care products, primarily through independent consultants, across four geographic segments: Asia, Europe, North America, and Latin America and Other. It also sells through digital channels. Approximately 71% of 2023 net sales were generated outside the United States.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $445.3 million | $421.9 million |
| Gross profit / margin | $321.1 million / 72.1% | $299.8 million / 71.0% |
| Operating income / margin | $18.7 million / 4.2% | $16.3 million / 3.8% |
| Net income | $16.4 million | $0.6 million |
| Net income (loss) attributable to common shareholders | $15.1 million; diluted EPS $0.77 | $(0.4) million; diluted EPS $(0.02) |
| Cash provided by operating activities | $41.2 million | $0.7 million |
| Cash and cash equivalents at year-end | $82.4 million | $60.0 million |
| Working capital at year-end | $89.1 million | $83.9 million |
Capital expenditures were $10.5 million, and financing activities used $8.0 million. The company had no outstanding balance on its $25.0 million revolving credit facility at year-end, with the full facility available; it reported no outstanding balance under its other credit agreement. Of year-end cash, $67.0 million was held in foreign markets and may be subject to repatriation taxes or restrictions. Operating lease liabilities totaled $14.9 million.
Changes versus FY2022
- Net sales rose 5.5% reported and 7.3% in local currencies; foreign exchange reduced reported sales by approximately $7.5 million.
- Asia sales increased 8.0% (12.7% in local currencies), Europe 2.7%, and North America 4.9%; Latin America and Other declined 1.1% (3.5% in local currencies). Taiwan sales grew 27.3%, while South Korea declined 9.3%.
- Gross margin improved by 1.1 percentage points, attributed to mix, price increases, and margin initiatives, partly offset by inflation and currency effects. Volume incentives declined to 30.4% of sales from 30.9%.
- SG&A increased $13.9 million to $167.1 million and rose to 37.5% of sales from 36.3%, reflecting compensation, marketing, China service fees, sales-related costs, strategic investments, and the Japan fraud incident.
- The effective tax rate fell to 18.7% from 96.4%, primarily because FY2022 included a substantial valuation allowance against deferred tax assets. The company cautions that its effective rate may fluctuate significantly.
Outlook, risks, and unusual items
- Outlook: No quantified revenue or earnings guidance is provided in the filing. Management believes cash from operations and available cash will fund normal operating needs and capital expenditures in the short and long term.
- Japan fraud and controls: A February 2023 social-engineering scheme caused $4.8 million of unauthorized wire transfers at the company’s Japan subsidiary. The company recorded a total $5.7 million pretax SG&A charge, including investigation and professional costs net of recoveries. Management and Deloitte concluded that a material weakness in controls over wire transfers remained unremediated at December 31, 2023; management’s disclosure controls were also deemed ineffective. Deloitte issued an adverse opinion on internal control over financial reporting, while expressing an unqualified opinion on the financial statements.
- Geopolitical exposure: Russia and Other markets, including Russia, Ukraine, Belarus, and other regional markets, represented 12.2% of net sales. Management expects the Russia-Ukraine conflict to continue affecting the business; further escalation, sanctions, operational disruption, or currency and payment restrictions could hurt sales, earnings, and cash flows.
- Other key risks: Consultant retention and productivity; direct-selling, product, advertising, and dietary-supplement regulation; product liability; foreign exchange; inflation and consumer demand; supply-chain and manufacturing disruptions; China product registrations and joint-venture exposure; cybersecurity and privacy; and tax or transfer-pricing disputes.
- Contingencies: The company accrued $0.2 million for non-income-tax contingencies and $0.5 million for other litigation. It estimated possible future payments of $0–$3.4 million for non-income-tax matters and $0–$0.4 million for other litigation; outcomes and timing are uncertain.
- The company repurchased 424,000 shares for $6.4 million in 2023; $17.6 million remained authorized. No dividend was paid.
Important facts for investors to verify
- Whether the wire-transfer control weakness has been remediated and tested as effective, and whether any further losses or control issues arise.
- How much of the $82.4 million cash balance is practically available for U.S. operations after foreign repatriation restrictions and taxes.
- Whether sales growth and margin improvements persist, especially in Taiwan, South Korea, North America, and digital channels, and how currency movements affect reported results.
- Potential effects of the Russia-Ukraine conflict, China regulatory requirements, consultant-network concentration, and any material changes in direct-selling rules.
- Realizability of deferred tax assets and expiring foreign tax credits, and any changes in tax assessments, litigation, or other contingencies.